Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Jun 2023
Historique:
received: 28 04 2023
revised: 26 05 2023
accepted: 05 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that

Identifiants

pubmed: 37372990
pii: ijms24129843
doi: 10.3390/ijms24129843
pmc: PMC10298094
pii:
doi:

Substances chimiques

Dihydrouracil Dehydrogenase (NADP) EC 1.3.1.2
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI18/00050
Organisme : Instituto de Salud Carlos III
ID : PI21/00145
Organisme : Instituto de Salud Carlos III
ID : PI22/00128
Organisme : Instituto de Salud Carlos III
ID : FI19/00061
Organisme : Instituto de Salud Carlos III
ID : JR21/00003
Organisme : Instituto de Salud Carlos III
ID : CA22/00002

Références

Oncol Rep. 2006 Jun;15(6):1533-9
pubmed: 16685392
Front Oncol. 2018 Jul 24;8:267
pubmed: 30087852
Eur J Hum Genet. 2020 Apr;28(4):508-517
pubmed: 31745289
Theranostics. 2022 Feb 7;12(5):2115-2132
pubmed: 35265202
Chem Res Toxicol. 2019 Aug 19;32(8):1469-1486
pubmed: 31353895
Pharmacogenomics J. 2019 Apr;19(2):164-177
pubmed: 29662106
J Clin Oncol. 2015 Dec 10;33(35):4219-26
pubmed: 26503202
Ther Drug Monit. 2016 Aug;38(4):423-31
pubmed: 26960170
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445588
Pharmacogenet Genomics. 2017 Jun;27(6):213-222
pubmed: 28445188
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Int J Mol Sci. 2021 Aug 12;22(16):
pubmed: 34445366
Cancer Cell Int. 2019 Jul 19;19:188
pubmed: 31360122
Clin Pharmacol Ther. 2018 Feb;103(2):210-216
pubmed: 29152729
J Clin Oncol. 2023 Apr 10;41(11):1999-2006
pubmed: 36735893
J Clin Oncol. 2009 Apr 20;27(12):2038-45
pubmed: 19307503
Transl Res. 2018 Oct;200:1-17
pubmed: 30053382
Pharmgenomics Pers Med. 2017 Feb 28;10:61-68
pubmed: 28280378
Pancreas. 2011 Jul;40(5):657-63
pubmed: 21487324
PLoS One. 2012;7(6):e38150
pubmed: 22761669
Clin Pharmacol Ther. 2013 Aug;94(2):252-9
pubmed: 23820299
Exp Ther Med. 2021 Jan;21(1):98
pubmed: 33363609
Oncogene. 2013 Mar 7;32(10):1274-83
pubmed: 22543588
Asia Pac J Clin Oncol. 2017 Apr;13(2):e11-e20
pubmed: 26792652
Pharmacogenomics J. 2020 Apr;20(2):179-191
pubmed: 31616045
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640195
Pharmacogenomics J. 2010 Feb;10(1):54-61
pubmed: 19786980
Clin Pharmacol Ther. 2013 Aug;94(2):243-51
pubmed: 23588304
J Clin Oncol. 2022 Feb 20;40(6):586-597
pubmed: 34985920
PLoS One. 2014 Dec 31;9(12):e115869
pubmed: 25551397
Curr Med Chem. 2016;23(12):1268-85
pubmed: 26965183
Pharmacogenomics. 2011 Jun;12(6):797-808
pubmed: 21605004
Eur Respir Rev. 2021 Oct 5;30(162):
pubmed: 34615702
Chem Soc Rev. 2019 Jan 21;48(2):540-557
pubmed: 30499573
Clin Cancer Res. 2019 Feb 15;25(4):1147-1155
pubmed: 30305294
J Clin Oncol. 2006 May 20;24(15):2237-44
pubmed: 16636344
Oncotarget. 2016 Aug 23;7(34):55741-55756
pubmed: 27248474
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancer. 2012 Apr 1;118(7):1856-67
pubmed: 21887680
Diagnostics (Basel). 2023 Mar 15;13(6):
pubmed: 36980426
Ann Surg Oncol. 2022 Oct;29(11):6497-6500
pubmed: 35838905
Transl Lung Cancer Res. 2020 Jun;9(3):819-823
pubmed: 32676345
Epigenetics. 2018;13(3):251-263
pubmed: 29436261
Biochem Biophys Res Commun. 2003 Feb 7;301(2):358-63
pubmed: 12565868
Bioorg Chem. 2019 Jul;88:102925
pubmed: 31003078
Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1103-6
pubmed: 17065072
Cancers (Basel). 2022 Jun 30;14(13):
pubmed: 35804978
Anticancer Res. 2012 May;32(5):1757-62
pubmed: 22593457
Sci Rep. 2019 Mar 5;9(1):3455
pubmed: 30837596
Biomed Res Int. 2013;2013:931028
pubmed: 24455740
Eur Heart J Cardiovasc Imaging. 2021 Mar 22;22(4):443-450
pubmed: 33152065
Pharmacogenet Genomics. 2021 Oct 1;31(8):177-184
pubmed: 34116532

Auteurs

Javier Guijarro-Eguinoa (J)

Clinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain.

Sara Arjona-Hernandez (S)

Laboratory Medicine Department, Puerta Del Mar University Hospital, 11009 Cadiz, Spain.

Stefan Stewart (S)

Clinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain.

Olga Pernia (O)

Cancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Pedro Arias (P)

Pharmacogenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.

Itsaso Losantos-García (I)

Biostatistics Department, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Tania Rubio (T)

Cancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Miranda Burdiel (M)

Cancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Carlos Rodriguez-Antolin (C)

Cancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Patricia Cruz-Castellanos (P)

Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.
Oncology Department, La Paz University Hospital, 28046 Madrid, Spain.

Oliver Higuera (O)

Oncology Department, La Paz University Hospital, 28046 Madrid, Spain.

Alberto M Borobia (AM)

Clinical Pharmacology Department, La Paz University Hospital, 28046 Madrid, Spain.

Sonia Rodriguez-Novoa (S)

Genetics of Metabolic Diseases Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.

Javier de Castro-Carpeño (J)

Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.
Oncology Department, La Paz University Hospital, 28046 Madrid, Spain.

Inmaculada Ibanez de Caceres (I)

Cancer Epigenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.
Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.

Rocio Rosas-Alonso (R)

Experimental Therapies and Novel Biomarkers in Cancer, Hospital La Paz Institute for Health Research-IdiPAZ, 28029 Madrid, Spain.
Pharmacogenetics Laboratory, Genetics Department, La Paz University Hospital, 28046 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH